Related Experiment Video
Updated: Jun 29, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
A Bee Trp-Arg Dense Peptide with Antiproliferation Efficacy against the Prostate Cancer Cell Line DU145
Ye-Eun Kim1, Ki-Young Kim1,2
1Graduate School of Biotechnology, Kyung Hee University, Seocheon, Giheung, Yongin 17104, Republic of Korea.
Abstract:
Prostate cancer accounts for 14% of male cancer-related fatalities in the UK. Given the challenges associated with hormone-based therapies in the context of androgen-independent prostate cancer, there is an imperative need for research into anticancer drugs. N0821, a peptide belonging to the Trp-Arg dense region and derived from the homologous region of various bee species, shows substantial potential for an anticancer effect. Both MTT assays and 3D spheroid assays were conducted to substantiate its antiproliferation potential and strongly indicated the antiproliferation effect of N0820 (WWWWRWWRKI) and N0821 (YWWWWRWWRKI). Notably, the mechanism underlying this effect is related to the downregulation of CCNA2 and the upregulation of CCNE1. Cell cycle arrest results from the reduction of CCNA2 in the S/G2 phase, leading to the accumulation of CCNE1. Our peptides were predicted to make an α-helix structure. This can act as an ion channel in the cell membrane. Therefore, we analyzed genes implicated in the influx of calcium ions into the mitochondria. Trp-Arg dense-region peptides are known for their antibacterial properties in targeting cell membranes, making the development of resistance less likely. Hence, further research in this area is essential and promising.
Insights
New bee-derived peptides, N0820 and N0821, show significant anticancer effects against prostate cancer cells by disrupting cell cycles. Further research is crucial for developing novel prostate cancer therapies.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Prostate cancer is a leading cause of cancer-related death in UK males.
- Hormone-based therapies face challenges with androgen-independent prostate cancer, necessitating new drug research.
- Bee-derived peptides offer a promising avenue for novel anticancer drug development.
Purpose of the Study:
- To investigate the antiproliferative potential of novel peptides N0820 and N0821 against prostate cancer cells.
- To elucidate the mechanism of action of these peptides, focusing on cell cycle regulation.
- To explore the potential of Trp-Arg dense-region peptides as anticancer agents.
Main Methods:
- MTT assays and 3D spheroid assays were used to assess antiproliferation.
- Gene expression analysis focused on CCNA2 and CCNE1.
- Analysis of genes involved in mitochondrial calcium ion influx was performed.
Main Results:
- Peptides N0820 and N0821 demonstrated significant antiproliferation effects.
- The mechanism involves downregulation of CCNA2 and upregulation of CCNE1, causing S/G2 cell cycle arrest.
- Peptides' predicted alpha-helix structure suggests potential ion channel activity.
Conclusions:
- N0820 and N0821 exhibit potent anticancer activity against prostate cancer.
- The identified mechanism of cell cycle disruption offers a novel therapeutic strategy.
- Trp-Arg dense-region peptides represent a promising class of anticancer agents with low resistance potential.
